ProMIS Neurosciences, Inc. announced that on January 3, 2024, the company announced that it separated with Gail Farfel, Ph.D. as President and principal executive officer of the Company, and as a member of the Board of Directors of the Company, in each case, effective as of December 30, 2023. Effective December 30, 2023, the Board appointed Neil Warma as President and principal executive officer of the Company. In connection with the Appointment, Mr. Warma resigned from his positions as Chair of the Compensation Committee of the Board, as a member of the Compensation Committee, and as a member of the Audit Committee of the Board.

Mr. Warma will continue to serve on the Board. Mr. Warma joined the Board of Directors of the ProMIS in May 2021. Mr. Warma has been a healthcare entrepreneur for over 25 years having managed and advised numerous biotechnology and pharmaceutical companies across the globe.

Previously, Mr. Warma served as the President and CEO and member of the board of Directors of Genexine, Inc., from April 2022 to October 2023. Additionally, Mr. Warma served as the General Manager of I-Mab Biopharma U.S. from September 2019 until May 2022. Mr. Warma was founder and from 2018 to 2019 served as CEO of Biohealth Care, LLC.

Previously, Mr. Warma was President and CEO and a member of the board of directors of Opexa Therapeutics, Inc. from 2008 to 2017. He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions at Novartis AG in Basel, Switzerland. Mr. Warma has served as a director for Genexine Ltd., and Biotechnology Innovation Organization since March 2021 and November 2020, respectively.

Mr. Warma earned a Bachelor of Science degree in Neuroscience from the University of Toronto and a Master of Business Administration from York University.